David H Kirn

David H. Kirn is an American entrepreneur and scientist. He is co-Founder, co-Chairman and CEO of 4D Molecular Therapeutics (4DMT, which he founded with David Schaffer in 2013), a biotechnology company working on adeno-associated virus gene therapy vectors. Prior to 4DMT, Kirn was Founder and CEO of Jennerex (2003-2013) and Vice President of Clinical Research at Onyx Pharmaceuticals (1994-2000).

Kirn has held academic positions at the University of California, San Francisco Medical School; the University of Oxford; and was chief medical resident at Harvard Medical School. His published work on oncolytic adenoviruses includes Onyx-015 and has appeared in Nature. He has co-authored over 100 publications in peer-reviewed journals.